Current role of cabozantinib in metastatic castration-resistant prostate cancer

Expert Review of Anticancer Therapy

Volumn 15, Issue 2, 2015, Pages 151-156

  Fay, André P ^a,b   Albiges, Laurence ^a,c   Bellmunt, Joaquim ^a,d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d HOSPITAL DEL MAR   (Spain)

Author keywords

bone metastasis; cabozantinib; castration resistant prostate cancer; MET; VEGF; XL 184

Indexed keywords

ABIRATERONE; CABOZANTINIB; DOCETAXEL; ENZALUTAMIDE; FLT3 LIGAND; MITOXANTRONE; ONCOPROTEIN; PREDNISONE; PROTEIN AXL; PROTEIN RET; SCATTER FACTOR RECEPTOR; STEM CELL FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; ANILIDE; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIDINE DERIVATIVE;

ABDOMINAL PAIN; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BODY WEIGHT DISORDER; BONE MASS; BONE METASTASIS; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CELL DIFFERENTIATION; CONSTIPATION; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; FATIGUE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; LUNG EMBOLISM; NAUSEA; NONHUMAN; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; VOMITING; ANIMAL; ANTAGONISTS AND INHIBITORS; BONE NEOPLASMS; MALE; METASTASIS; PATHOLOGY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; QUALITY OF LIFE; SECONDARY; SURVIVAL RATE;

ANILIDES; ANIMALS; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; HUMANS; MALE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTEIN KINASE INHIBITORS; PYRIDINES; QUALITY OF LIFE; RECEPTOR PROTEIN-TYROSINE KINASES; SURVIVAL RATE;

EID: 84921478581     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.2015.1003047     Document Type: Review

References (49)

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN. 2008. Int J Cancer 2010; 127(12):2893-917
2. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64(1):9-29
3. DeSantis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2014. Cancer J Clin 2014;64(4):252-71
4. Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract 2011;65(11):1180-92
5. Halabi S, Vogelzang NJ, Kornblith AB, et al. Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. J Clin Oncol 2008;26(15):2544-9
6. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502-12
7. Berthold DR, Pond GR, de Wit R, Investigators TAX. Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. Ann Oncol 2008;19(10):1749-53
8. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364(21):1995-2005
9. Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet 2012;13(10):983-92
10. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367(13):1187-97
11. Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368(2):138-48
12. Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014;371(5):424-33
13. Parker C, Sartor O. Radium-223 in prostate cancer. N Engl J Med 2013;369(17): 1659-60
14. Saad F. Zoledronic acid significantly reduces pathologic fractures in patients with advanced-stage prostate cancer metastatic to bone. Clin Prostate Cancer 2002;1(3): 145-52
15. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011;377(9768):813-22
16. Nakashiro K, Hayashi Y, Oyasu R. Immunohistochemical expression of hepatocyte growth factor and c-Met/HGF receptor in benign and malignant human prostate tissue. Oncology 2003;10(5): 1149-53
17. Andrea Borghese Apolo YT, Lee M-J, Lee S, et al. Effect of cabozantinib on immunosuppressive subsets in metastatic urothelial carcinoma. J Clin Oncol 2014; 32(5s Suppl):abstract 4501
18. Cecchi F, Rabe DC, Bottaro DP. Targeting the HGF/Met signaling pathway in cancer therapy. Expert Opin Ther Targets 2012; 16(6):553-72
19. Zhang S, Zhau HE, Osunkoya AO, et al. Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells. Mol Cancer 2010;9:9
20. Yakes FM, Chen J, Tan J, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 2011; 10(12):2298-308
21. Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15(3):220-31
22. Nguyen HM, Ruppender N, Zhang X, et al. Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling. PLoS One 2013;8(10):e78881
23. Dai J, Zhang H, Karatsinides A, et al. Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions. Clin Cancer Res 2014;20(3):617-30
24. Sennino B, Ishiguro-Oonuma T, Wei Y, et al. Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Dis 2012; 2(3):270-87
25. Eder JP, Vande Woude GF, Boerner SA, LoRusso PM. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 2009;15(7):2207-14
26. Elisei R, Schlumberger MJ, Muller SP, et al. Cabozantinib in progressive medullary thyroid cancer. Clin Cancer Res 2013; 31(29):3639-46
27. Gordon MS VN, Schoffski P, et al. Activity of cabozantinib (XL184) in soft tissue and bone: Results of a phase II randomized discontinuation trial (RDT) in patients (pts) with advanced solid tumors. J Clin Oncol 2011;29(196s Suppl):abstract3010
28. Smith DC, Smith MR, Sweeney C, et al. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol 2013;31(4):412-19
29. Smith MR, Sweeney CJ, Corn PG, et al. Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study. J Clin Oncol 2014;32(30): 3391-9
30. Basch E, Autio KA, Smith MR, et al. Effects of Cabozantinib on Pain and Narcotic Use in Patients with Castration-resistant Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohort. Eur Urol 2014. [Epub ahead of print]
31. Scher HI SM, Sweeney C, et al. An exploratory analysis of bone scan lesion area (BSLA), circulating tumor cell (CTC) change, pain reduction, and overall survival (OS) in patients (pts) with castrationresistant prostate cancer (CRPC) treated with cabozantinib (cabo): Updated results of a phase II nonrandomized expansion (NRE) cohort. J Clin Oncol 2013;31:abstract 5026
32. Kurzrock R, Sherman SI, Ball DW, et al. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 2011;29(19):2660-6
33. Lee RJ, Saylor PJ, Michaelson MD, et al. A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases. J Clin Oncol 2013; 19(11):3088-94
34. Grano M, Galimi F, Zambonin G, et al. Hepatocyte growth factor is a coupling factor for osteoclasts and osteoblasts in vitro. Proc Natl Acad Sci USA 1996;93(15): 7644-8
35. Knudsen BS, Gmyrek GA, Inra J, et al. High expression of the Met receptor in prostate cancer metastasis to bone. Urology 2002;60(6):1113-17
36. Humphrey PA, Zhu X, Zarnegar R, et al. Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol 1995;147(2):386-96
37. Street J, Lenehan B. Vascular endothelial growth factor regulates osteoblast survival-evidence for an autocrine feedback mechanism. J Orthop Surg 2009;4:19
38. Lee RJ, Smith MR. Targeting MET and vascular endothelial growth factor receptor signaling in castration-resistant prostate cancer. Cancer J 2013;19(1):90-8
39. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008;26(7):1148-59
40. Vuong W, Sartor O, Pal SK. Radium-223 in metastatic castration resistant prostate cancer. Asian J Androl 2014;16(3):348-53
41. Michaelson MD, Oudard S, Ou YC, et al. Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer. J Clin Oncol 2014;32(2):76-82
42. Tannock IF, Fizazi K, Ivanov S, et al. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. Lancet Oncology 2013;14(8):760-8
43. Sonpavde G, Periman PO, Bernold D, et al. Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. Ann. Oncol 2010;21(2):319-24
44. Kelly WK, Halabi S, Carducci M, et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol 2012;30(13):1534-40
45. A study of cabozantinib (XL184) vs everolimus in subjects with metastatic renal cell carcinoma (METEOR). Available from: https://clinicaltrials.gov/ct2/show/ NCT01865747
46. Study of cabozantinib (XL184) vs placebo in subjects with hepatocellular carcinoma who have received prior sorafenib (CELESTIAL). Available from: https:// clinicaltrials.gov/ct2/show/NCT01908426? term=NCT01908426&rank=1
47. A dose escalation study of the safety and pharmacokinetics of GSK1363089 (Formerly XL880) administered orally daily to subjects with solid tumors. Available from: https://clinicaltrials.gov/ct2/show/ NCT00743067? term=GSK1363089&rank=2
48. A study of E7050 administered orally to patients with advanced solid tumors. Available from: https://clinicaltrials.gov/ct2/ show/NCT00921869? term=NCT00921869&rank=1
49. Safety study of oral mgcd265 administered without interruption to subjects with advanced malignancies. Available from: https://clinicaltrials.gov/ct2/show/ NCT00697632? term=NCT00697632&rank=1